Tier 2 — strong

Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer

Susanne M Henning, Piwen Wang, Ru-Po Lee, Amy Trang, George Husari, Jieping Yang, Emma M Grojean, Austin Ly, Mark Hsu, David Heber, Tristan Grogan, Zhaoping Li, William J Aronson
Food & function 2020 11(5):4114-4122

Bibliography

PubMed
PMID 32347270
PubMed Central
PMC8312236
DOI
10.1039/d0fo00565g
Funding
Indexed grant support: P50 CA092131 — NCI NIH HHS — United States; R01 CA231219 — NCI NIH HHS — United States; R03 CA171583 — NCI NIH HHS — United States. The indexed list may not contain the complete funding declaration.
Competing interests
Reported disclosure: There are no conflicts of interest to declare.

Study snapshot

DesignRandomized parallel placebo-controlled presurgical study
ModelHuman intervention research
Sample31 men with prostate cancer
InterventionGreen-tea extract 1 g/day plus quercetin 800 mg/day versus green-tea extract plus placebo
Duration4 weeks before prostatectomy
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2020, this source examined prostate and urinary health. Design: Randomized parallel placebo-controlled presurgical study. Sample/model: 31 men with prostate cancer. The exposure or intervention was Green-tea extract 1 g/day plus quercetin 800 mg/day versus green-tea extract plus placebo. Follow-up or treatment period: 4 weeks before prostatectomy.

Quercetin exposure increased, but prostate green-tea-polyphenol content and methylation activity did not differ significantly.

Tissue pharmacokinetic study of a combination. Tumor regression, cancer prevention and improved survival were not tested.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Prostatitis and Chronic Pelvic Pain. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Quercetin exposure increased, but prostate green-tea-polyphenol content and methylation activity did not differ significantly.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Green-tea extract 1 g/day plus quercetin 800 mg/day versus green-tea extract plus placebo; 4 weeks before prostatectomy.

What this study can and cannot tell us

  • Tissue pharmacokinetic study of a combination. Tumor regression, cancer prevention and improved survival were not tested.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Adding collagen, propolis plus quercetin, bacillus coagulans, hyaluronic acid and chondroitin sulphate to D-mannose avoids symptoms and prevents recurrence in women with recurrent urinary tract infections: a single-blind randomized controlled trial
Gaetano Riemma et al. · Expert review of anti-infective therapy · 2025
Tier 2
Efficacy of an orally administered combination of hyaluronic acid, chondroitin sulfate, curcumin and quercetin for the prevention of recurrent urinary tract infections in postmenopausal women
M Torella et al. · European journal of obstetrics, gynecology, and reproductive biology · 2016

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology